2026 IPO Train Keeps Chugging as AgomAb, SpyGlass Eye Nasdaq Debut

Why It Matters

The offerings inject fresh capital into late‑stage ophthalmology and gastro‑intestinal therapeutics, accelerating paths to market and underscoring sustained investor confidence in biotech innovation.

Key Takeaways

• SpyGlass targets glaucoma with Phase III bimatoprost implant.
• AgomAb develops ALK5 inhibitor for fibrostenosing Crohn’s.
• Both IPOs list on Nasdaq, expanding biotech capital markets.
• Funds will finance late‑stage trials and product launch.
• 2026 biotech IPO wave signals strong investor appetite.

Pulse Analysis

The 2026 IPO surge reflects a broader market appetite for high‑growth biotech assets, especially those poised to address chronic, high‑prevalence conditions. Nasdaq’s Global Select and Global Market platforms continue to attract companies seeking visibility and liquidity, while investors chase pipelines that promise differentiated mechanisms of action. By joining peers such as Veradermics, Eikon Therapeutics, and Aktis Oncology, SpyGlass and AgomAb reinforce the narrative that venture‑backed biopharma can secure public funding without compromising scientific rigor.

SpyGlass Pharma’s bimatoprost‑eluting intraocular lens tackles a sizable unmet need in glaucoma management. Traditional eye‑drop therapies suffer from adherence challenges, whereas an implanted device delivering sustained prostaglandin analog could dramatically improve intra‑ocular pressure control post‑cataract surgery. With Phase III enrollment targeting 400 patients per study and a projected 2028 regulatory filing, the company stands to capture a share of a market projected to exceed $5 billion globally. Successful approval would also validate the broader concept of drug‑device combinations in ophthalmology, potentially opening pathways for similar platforms.

AgomAb Therapeutics focuses on fibrostenosing Crohn’s disease, a complication lacking effective oral treatments. Ontunisertib’s selective ALK5 inhibition aims to modulate fibrotic pathways directly within the gastrointestinal tract, differentiating it from systemic immunosuppressants. Ongoing Phase IIa data and an upcoming Phase IIb trial position the company to deliver pivotal efficacy signals before year‑end. If the drug demonstrates meaningful clinical benefit, it could address a high‑cost, high‑burden patient segment and attract partnership interest from larger pharmaceutical players seeking to expand their gastro‑enterology portfolios. Both firms’ IPO proceeds will be pivotal in de‑risking these late‑stage programs and accelerating time‑to‑revenue.